30433-91-1Relevant articles and documents
Application of the cyanurate-isocyanurate rearrangement to amine synthesis: Preparation of 2-(2-thienyl)ethylamine
Harrington,Sanchez
, p. 1307 - 1314 (1993)
This communication describes a new method for preparation of 2-(2-thienyl)ethylamine, an important pharmaceutical intermediate. The method is based on the O-to-N migration of an alkyl group via cyanurate-isocyanurate rearrangment.
Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids
Nguyen, Thuy,Gamage, Thomas F.,Decker, Ann M.,Finlay, David B.,Langston, Tiffany L.,Barrus, Daniel,Glass, Michelle,Harris, Danni L.,Zhang, Yanan
, (2021/05/26)
Allosteric modulation offers an alternate approach to target the cannabinoid type-1 receptor (CB1) for therapeutic benefits. Examination of the two widely studied prototypic CB1 negative allosteric modulators (NAMs) Org27569 and PSNCBAM-1 revealed structural resemblance and similar structure–activity relationships (SARs). In silico docking and dynamics simulation studies using the crystal structure of CB1 co-bound with CP55,940 and Org27569 suggested that Org27569 and PSNCBAM-1 occupied the same binding pocket and several common interactions were present in both series with the CB1 receptor. A new scaffold was therefore designed by merging the key structural features from the two series and the hybrids retained these binding features in the in silico docking studies. In addition, one such hybrid displayed similar functions to Org27569 in dynamic simulations by preserving a key R2143.50-D3386.30 salt bridge and maintaining an antagonist-like Helix3-Helix6 interhelical distance. Based on these results, a series of hybrids were synthesized and assessed in calcium mobilization, [35S]GTPγS binding and cAMP assays. Several compounds displayed comparable potencies to Org27569 and PSNCBAM-1 in these assays. This work offers new insight of the SAR requirement at the allosteric site of the CB1 receptor and provides a new scaffold that can be optimized for the development of future CB1 allosteric modulators.
1,2,5-oxadiazole derivative used as indoleamine 2,3-dioxygenase inhibitor
-
, (2019/10/01)
The invention belongs to the technical field of 1,2,5-oxadiazole derivatives, and particularly relates to a 1,2,5-oxadiazole derivative or a pharmaceutically acceptable salt thereof which is used as an indoleamine 2,3-dioxygenase inhibitor. The structure of the 1,2,5-oxadiazole derivative or the pharmaceutically acceptable salt thereof used as the IDO inhibitor is shown in the following formula I.The invention provides a general formula compound I with a novel structure. Experimental results show that some compounds have excellent IDO inhibitory activity and permeation performance at the sametime. The compound is expected to be marketed as a tumor molecular immunotherapeutic drug for cancer treatment.
Generation of novel family of reductases from PCR based library for the synthesis of chiral alcohols and amines
Sehajpal, Pallvi,Kirar, Seema,Ghosh, Saptarshi,Banerjee, Uttam Chand
, p. 83 - 91 (2018/08/17)
Biocatalysis has shown tremendous potential in the synthesis of drugs and drug intermediates in the last decade. Screening of novel biocatalysts from the natural genome space is the growing trend to replenish the harsh chemical synthetic routes, commonly used in the pharmaceutical and chemical industry. Here, we report a novel ketoreductase (KERD) and a nitrile reductase isolated from the PCR based library generated from the genome of Rhodococcus ruber and Bacillus subtilis, respectively. Both the proteins are hypothetical in nature as there is no putative homology found in the database, although both the enzymes have significant activity towards the synthesis of chiral alcohols and amines. Enzyme activity over a wide range of substrates (aromatic and aliphatic) for both the novel catalysts was observed. From the unique gene sequence to activity over a broad range of substrate and >99% conversion at higher concentrations (100 mM and above) entitles both the hypothetical enzymes as novel. The novel KERD has shown >99% selectivity for the synthesis of (S)-phenylethanol which makes it a potential candidate for industrial catalysis. The novel nitrile reductase has also shown promising activity for the synthesis of (R)-2-phenylethanolamine, which is a difficult moiety to synthesize chemically. In this report, starting from a homology based library, two highly potent whole cell biocatalysts are obtained.
Hydrogenation of Nitriles and Ketones Catalyzed by an Air-Stable Bisphosphine Mn(I) Complex
Weber, Stefan,St?ger, Berthold,Kirchner, Karl
supporting information, p. 7212 - 7215 (2018/11/25)
Efficient hydrogenations of nitriles and ketones with molecular hydrogen catalyzed by a well-defined bench-stable bisphosphine Mn(I) complex are described. These reactions are environmentally benign and atomically economic, implementing an inexpensive, earth-abundant nonprecious metal catalyst. A range of aromatic and aliphatic nitriles and ketones were efficiently converted into primary amines and alcohols, respectively, in good to excellent yields. The hydrogenation of nitriles proceeds at 100 °C with catalyst loading of 2 mol % and 20 mol % base (t-BuOK), while the hydrogenation of ketones takes place already at 50 °C, with a catalyst loading of 1 mol % and 5 mol % of base. In both cases, a hydrogen pressure of 50 bar was applied.
Benzhydrylamine: An effective aminating agent for the synthesis of primary amines
Sun, Quan-Wei,Xing, Jun-De,Qin, Yu-Hong,Yin, Xu-Wen,Zhou, Yi
, p. 181 - 183 (2018/05/26)
Aldehydes, ketones, alkyl toluene-p-sulfonates and halides are converted into the corresponding primary amines with benzhydrylamine as a valuable ammonia synthon in moderate to excellent yields.
Drug application for benzene [g] ceteroary [a, g] quinazine compound and preparation method thereof
-
Paragraph 0110; 0111, (2017/11/16)
The invention relates to a new application of a benzene [g] ceteroary [a, g] quinazine compound and a preparation method thereof. Specifically, the invention relates to the application of the benzene [g] ceteroary [a, g] quinazine compound in preparing the drug for treating and/or preventing the metabolic diseases caused by AMPK route, especially, the diabetes, adiposis, fatty liver and complication thereof caused by insulin resistance.
Industrial preparation method of 2-ethylamine-heterocyclic derivative
-
Paragraph 0057-0059, (2017/06/02)
The invention provides an industrial preparation method of a 2-ethylamine-heterocyclic derivative. The method is characterized in that a heteroaryl derivative and 2-substituent ethylene react to produce a 2-(2-cyanoethyl)-heterocyclic derivative, a 2-acetate-heterocyclic derivative and a 2-(3-butyl ketone)-heterocyclic derivative separately. The production method is simple and different from complicated production modes and harsh production conditions in the prior art. By means of the industrial preparation method, synthesis of a target product can be achieved by one step. As the production technology and synthetic route are optimized through the preparation method, in the production process, few side reactions occur, the aftertreatment is convenient, the production condition is mild, and the preparation method is suitable for an industrialized production mode.
An industrial preparation method for 2-substituted-thiophene derivatives
-
Paragraph 0039; 0040; 0041, (2017/08/28)
An industrial preparation method for 2-substituted-thiophene derivatives is provided. The method is characterized in that thiophene derivatives and nitroethylene are reacted to generate 2-(2-nitroethyl)-thiophene derivatives, the 2-(2-nitroethyl)-thiophene derivatives are oxidized to obtain 2-(2-carboxylic acid)-thiophene derivatives, and then the 2-ethylamine-thiophene derivatives can be obtained through reduction. The method is simple. Different from complex production manners and harsh production conditions in the prior art, synthesis of target products can be achieved by one step by the method. A production process and a synthesis route are optimized in the method, and therefore side reactions are less, after-treatment is convenient, and production conditions are mild in a production process, and the method is suitable for industrial production modes.
ORGANIC METAL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE EMPLOYING THE SAME
-
, (2016/07/05)
Organic metal compounds and organic electroluminescence devices employing the same are provided. The organic metal compound has a chemical structure represented below: wherein R1, R2, R3, R4, and R5 are independent and can be hydrogen, halogen, C1-8 alkyl or C1-8alkoxy; L can be acetylacetone ligand, picolinic acid ligand, N,N′-diisopropylbenzamidinate, or N,N′-diisopropyl-diisopropyl-guanidinate.
